Agenus Receives Fast Track Designation for Botensilimab and Balstilimab in Colorectal Cancer

Agenus Inc. has been granted Fast Track Designation from the US FDA for the investigation of the combination of botensilimab and balstilimab. The designation is for patients with non-microsatellite instability-high/deficient mismatch repair metastatic colorectal cancer with no active liver involvement.